Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia. A pilot, randomised, double-blind, dose-titrating study

Clinical Drug Investigation

Volumn 16, Issue 3, 1998, Pages 219-227

  Athyros, Vasilios C ^a,c   Papageorgiou, Athanasios A ^a   Hatzikonstandinou, Haris A ^a   Athyrou, Valasia V ^b   Kontopoulos, Athanasios G ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; FIBRINOGEN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031718239     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816030-00006     Document Type: Article

References (41)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20): 1301-7
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335 (14): 1001-9
3. The Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-9
4. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995; 117 (2): 237-44
5. Auerbach BJ, Krause BR, Bisgaier CL, et al. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis 1995; 115 (2): 173-80
6. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15 (5): 678-82
7. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996 10; 275 (2) :128-33
8. Athyros V, Papageorgiou A, Hagikonstantinou H, et al. Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidemia. Drug Invest 1994; 7 (3): 134-42
9. Kontopoulos A, Athyros V, Papageorgiou A, et al. Effects of simvastatin and ciprofibrate alone and in combination on apolipoprotein-B-containing lipoproteins and on low density lipoprotein subfraction distribution in patients with familial combined hyperlipidemia and coronary artery disease. Coron Artery Dis 1996; 7 (8-9): 843-50
10. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62 Suppl. J: 28-34
11. Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patters and risk of myocardial infarction. JAMA 1988; 260 (13): 1917-21
12. Tornvall P, Bävenholm P, Landou C, et al. Relation of plasma levels of apoprotein B-containing lipoproteins angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993; 88 (5 Pt 1): 2180-9
13. Chait A, Brazg RL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative miodification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94 (4): 350-6
14. Assmann G, Schulte H. Identification of individuals at high risk for myocardial infarction. Atherosclerosis 1994; 110 Suppl.: 11S-21S
15. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995; 2 (3): 197-205
16. Gotto AM. Lipid handbook for clinicians. Houston, Texas, USA: International Lipid Information Bureau, 1995
17. Athyros V, Papageorgiou A, Basagiannis E, et al. Pilot study of the effect on myocardial infarction risk profile of the simvastatin - ciprofibrate combination in patients with refractory familial combined hyperlipidaemia. Clin Drug Invest 1996; 11 (4): 196-204
18. Feher MD, Foxton J, Banks D, et al. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995; 74 (1): 14-7
19. Athyros V, Papageorgiou A, Hatzikonstandinou H, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80 (5): 608-13
20. Genest Jr J, Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol 1995; 76 Suppl. A: 8S-20S
21. Kehely A, MacMahon M, Barhir M, et al. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. QJM 1995; 88 (6): 421-7
22. Nakamura H. Dose-related reduction of LDL-cholesterol in patients with primary hypercholesterolemia by atorvastatin [abstract]. Atherosclerosis 1997; 134 Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9: Paris, France, 1997: 66
23. Nakamura H. Dose-related reduction of LDL-cholesterol in patients with primary hypercholesterolemia by atorvastatin [abstract]. Atherosclerosis 1997; 134 Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9: Paris, France, 1997: 66
24. Adeli K, Romain T, Mohammadi A, et al. Effects of atorvastatin on intracellular levels and stability of apolipoprotein B and HMG-CoA reductase in Hep G2 cells [abstract]. Atherosclerosis 1947; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Paris, France, 1997: 11
25. Adeli K, Romain T, Mohammadi A, et al. Effects of atorvastatin on intracellular levels and stability of apolipoprotein B and HMG-CoA reductase in Hep G2 cells [abstract]. Atherosclerosis 1947; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Paris, France, 1997: 11
26. de Oya M, Alvarez-Sala LA, Mata P, et al. The role of cholesterol in the pathogenesis of atherosclerosis. Primary and secondary causes of hyperlipidemia. In: Diez J, Dzau VJ, Ferrari R, et al., editors. Molecular cell biology of cardiovascular diseases. Madrid: Mosby/Doyma Libros, 1995: 149-79
27. Bergstrom JD, Bostedor RG, Rew DJ, et al. Responses to the inhibition of HMG-CoA reductase: a comparison of simvastatin and atorvastatin [abstract]. Atherosclerosis 1997; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Paris, France, 1997: 24
28. Bergstrom JD, Bostedor RG, Rew DJ, et al. Responses to the inhibition of HMG-CoA reductase: a comparison of simvastatin and atorvastatin [abstract]. Atherosclerosis 1997; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Paris, France, 1997: 24
29. Naoumova RP, Dunn S, Rallidis L, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin [Abstract]. Atherosclerosis 1997; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Pari,. France, 1997: 67
30. Naoumova RP, Dunn S, Rallidis L, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin [Abstract]. Atherosclerosis 1997; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Pari,. France, 1997: 67
31. Heinonen T, Black DM, Nawrocki JW. An overview of the clinical efficacy profile of atorvastatin [Abstract]. Atherosclerosis 1997; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Paris, France, 1997: 42
32. Heinonen T, Black DM, Nawrocki JW. An overview of the clinical efficacy profile of atorvastatin [Abstract]. Atherosclerosis 1997; 134. Abstract Issue of the XIth International Symposium on Atherosclerosis; 1997 Oct 5-9; Paris, France, 1997: 42
33. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80 (1): 39-44
34. Bertolini S, Bittolo Bon C, Campbell M, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130 (1-2): 191-7
35. Jones P, Kafonek S, Laurova I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. (The CURVES Study). Am J Cardiol 1998; 81 (5): 582-7
36. Marais AD, Firth JC, Bateman ME, et al. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17(8): 1527-31
37. Wierzbicki AS, Lumb PJ, Semra YK, et al. Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351 (9102): 569-70
38. Darko DA, O'Shea D. Statins and fibrinogen. Lancet 1998; 351 (9113): 1431
39. Haverkate F, Koopman J, de Maat MP. Statins and fibrinogen. Lancet 1998; 351 (9113): 1430-1
40. Black DM. Statins and fibrinogen. Lancet 1998; 351 (9113): 1430
41. Nair DR, Papadakis JA, Jagroop IA, et al. Statins and fibrinogen. Lancet 1998; 351 (9113): 1430